Robust Recombinant Antibody Engineering: Equivalency Studies Of Biosimilar Monoclonal Antibodies

In research, biosimilar monoclonal antibodies are frequently used as cost-effective alternatives for studying and characterizing specific disease targets in cancer, inflammatory disease, and autoimmune disease. Leveraging decades of antibody manufacturing experience from R&D Systems, Bio-Techne pioneers the development of biosimilar antibodies through our cutting-edge recombinant engineering and expression platform.

In this white paper, we demonstrate that Bio-Techne’s research-use only biosimilar antibodies are equivalent to the original therapeutic antibodies in terms of functionality, kinetics, and surface charge. Discover why Bio-Techne's biosimilar antibodies are the most similar biosimilar antibodies.

Request your copy of this white paper to learn about:

• Bio-Techne’s biosimilar antibody pipeline
• Equivalency studies for biosimilar monoclonal antibodies
  • Direct ELISA binding studies
  • Capillary isoelectric focusing (cIEF) profiles
  • Binding kinetics
  • Bridging assay
• Robustness of Bio-Techne’s recombinant antibody engineering services